Phase II trial of DX 2930 in patients with hereditary angioedema.

Trial Profile

Phase II trial of DX 2930 in patients with hereditary angioedema.

Planning
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2015

At a glance

  • Drugs Lanadelumab (Primary)
  • Indications Hereditary angioedema
  • Focus Therapeutic Use
  • Sponsors Dyax
  • Most Recent Events

    • 24 Feb 2015 According to a Dyax media release, this trial is expected to start in the second half of 2015.
    • 10 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top